PHOTO
Dubai: Takeda Pharmaceutical Company Limited (TSE.:4502/NYSE: TAK) ("Takeda"), has announced a new office address, bringing together its ICMEA geographies (India, CIS countries, the Middle East, Turkey and Africa) at a new strategic location in Dubai. The new Area offices based at One Central at Dubai World Trade Centre is recognized for its green credentials, achieving Gold level certification by LEED standards, with Takeda's offices receiving Silver level certification.
Recognizing that climate change poses a risk to human health, including the spread of infectious diseases, Takeda has made environmental efforts a priority. To date, Takeda has met and exceeded its previously established 2020 environmental goals ahead of schedule, including reducing its CO2 emissions by 33.7% compared to 2005 levels.
Mahender Nayak, Senior VP and Area Head of Takeda, ICMEA, commented: "Following Takeda's recent 239th birthday as a company, we felt it felt opportune to introduce the new state-of-the-art facility, merging the worlds of science and Japanese tradition to provide a refreshed environment to our team members. Housing the hub team for the ICMEA Area, we are committed to advancing our sustainability goals while boosting employee wellness and connectivity. Takeda's values of Integrity, Honesty, Fairness, and Perseverance guide us in our obligation to protect the environment and our patients and motivate us to act urgently on climate change."
Key LEED initiatives for this New office space include:
- Achieve 12.3% savings on Energy Use set by the globally recognized ASHRAE 90.1-2010 baseline.
- Improve air quality – the premise has ample fresh air solutions as per the ASHRAE 62.1–2010 requirements, which helps in controlling pollutant sources, removing contaminants, and enhancing occupant health and comfort.
His Excellency Helal Saeed Almarri, Director General, Dubai World Trade Centre Authority (DWTCA) and Dubai Department of Tourism and Commerce Marketing (DTCM) said, "The DWTC Authority (DWTCA) is delighted to welcome Takeda Pharmaceutical Company Limited (Takeda) to the One Central development and congratulate them on their milestone company anniversary. As one of the world's leading global biopharmaceutical companies, relocating their new area offices for ICMEA to One Central to cover a wider geographic area emphasizes both the strategic importance of the development and supports Dubai's attractiveness to international corporations as a global dynamic business destination of choice. DWTCA's One Central development continues to deliver a distinctive proposition that highlights Dubai's global status as a progressive, technologically advanced hub for international business."
Located within the DWTCA free zone, the commercial offering at One Central is complemented by a world-class mixed-use lifestyle destination. The free zone provides an ideal environment for leading companies and offers the highest technology and infrastructure standards to meet the needs of modern corporations and businesses.
Tracing Takeda's roots in Japan back to 1781, the Takeda's new office carefully curates Japanese elements. The design details are subtly reflected in the corporate philosophy in its four values: Integrity, Fairness, Honesty, and Perseverance. Takeda's ICMEA business is part of its Growth & Emerging Business Unit (GEM), one of four Regional Business Units that make-up its worldwide commercial operations: The US, Japan, Europe & Canada (EUCAN) and GEM.
-Ends-
Contact persons for press inquiries:
Jai Tolani
Associate Director
FleishmanHillard
jai.tolani@fleishman.com
About Takeda's Growth & Emerging Markets Business Unit
Led from its Regional offices in Singapore, Takeda's Growth & Emerging Markets Business Unit (GEM BU), is committed to addressing patient unmet medical needs wherever it operates. This includes those parts of the world with some of the most substantial healthcare burdens.
The GEM BU is primarily focused on delivering medical innovation to patients in the areas of Oncology, Gastroenterology, Plasma Derived Therapies, and Rare Diseases, via a direct presence that spans almost 50 geographies including Brazil, China, and Russia. These three countries, in addition to three Area operations* with hubs in South America, the Middle East, and Asia Pacific, are of particular focus as part of the Region's ambition to deliver sustainable, profitable growth via our commercial activities, and to increase the number of patients lives positively impacted via the Company's approaches to Access to Medicines.
GEM BU also aspires to be viewed as 'Best-in-Class' in the eyes of patients, customers, and its employees. Currently, within the Region, a total of 24 local Takeda operations have been externally recognized as a 'top employer' by the Top Employer Institute.
*ICMEA - India, CIS, the Middle East & Africa led from Dubai, UAE
SAM - South Cone, Andean & Mexico led from Buenos Aires, Argentina
APAC - Asia Pacific led from Singapore
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
